AAA
Affinity Asset Advisors Portfolio holdings
AUM
$1.39B
1-Year Est. Return
230.19%
This Fund
S&P 500
1 Year Est. Return
+230.19%
AUM
$1.07B
AUM Growth
+$399M
(+59%)
Holding
110
Top Buys
| 1 | +$54.2M | |
| 2 | +$18.4M | |
| 3 | +$15.9M | |
| 4 |
Soleno Therapeutics
SLNO
|
+$14.8M |
| 5 |
Cytokinetics
CYTK
|
+$14.4M |
Top Sells
| 1 | +$32M | |
| 2 | +$12.5M | |
| 3 | +$8.84M | |
| 4 |
INZY
Inozyme Pharma
INZY
|
+$7M |
| 5 |
Vera Therapeutics
VERA
|
+$5.59M |
Sector Composition
| 1 | Healthcare | 91.07% |
| 2 | Financials | 0.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VRNA
1
DELISTED
Verona Pharma
VRNA
| $66.7M | 6.21% |
625,000
+15,000
|
|
||
2
Insmed
INSM
$31.2B
| $64.8M | 6.03% |
450,000
-25,000
|
|
||
3
State Street SPDR S&P 500 ETF Trust
SPY
$695B
| $56.3M | 5.24% |
+84,490
|
|
||
4
Xenon Pharmaceuticals
XENE
$3.29B
| $56.2M | 5.23% |
1,400,000
+300,000
|
|
||
5
Madrigal Pharmaceuticals
MDGL
$9.89B
| $52.7M | 4.91% |
115,000
+35,000
|
|
||
6
Apogee Therapeutics
APGE
$4.85B
| $46.6M | 4.34% |
1,173,426
+481,527
|
|
||
7
Arcellx
ACLX
$6.59B
| $41M | 3.82% |
500,000
+5,000
|
|
||
8
Alkermes
ALKS
$4.99B
| $37.5M | 3.49% |
1,250,000
+250,000
|
|
||
9
Nuvalent
NUVL
$7.87B
| $33.2M | 3.09% |
384,417
-30,583
|
|
||
|
ABVX
10
Abivax
ABVX
$8.94B
| $30.6M | 2.84% |
360,000
+260,000
|
|
||
11
Mineralys Therapeutics
MLYS
$2.32B
| $28.4M | 2.65% |
750,000
-150,000
|
|
||
12
Teva Pharmaceuticals
TEVA
$39.3B
| $28.3M | 2.63% |
1,400,000
|
|
||
|
MRUS
13
DELISTED
Merus
MRUS
| $26.9M | 2.5% |
285,769
+215,769
|
|
||
|
CNTA
14
Centessa Pharmaceuticals
CNTA
$3.92B
| $26.8M | 2.5% |
1,107,162
+207,000
|
|
||
15
Lexeo Therapeutics
LXEO
$520M
| $25.7M | 2.39% |
3,870,527
+281,172
|
|
||
16
Trevi Therapeutics
TRVI
$1.61B
| $25.6M | 2.38% |
2,800,000
+265,942
|
|
||
17
Spyre Therapeutics
SYRE
$3.34B
| $23.8M | 2.21% |
1,419,299
+812,621
|
|
||
18
Rezolute
RZLT
$300M
| $19.7M | 1.84% |
2,100,000
-100,000
|
|
||
|
19
Cytokinetics
CYTK
$7.51B
| $19.2M | 1.79% |
+350,000
|
|
||
|
ORKA
20
Oruka Therapeutics
ORKA
$1.63B
| $18.4M | 1.72% |
959,180
+355,701
|
|
||
21
uniQure
QURE
$654M
| $17.5M | 1.63% |
300,000
+165,000
|
|
||
22
Wave Life Sciences
WVE
$2.57B
| $15.4M | 1.43% |
2,100,000
+99,692
|
|
||
23
Protagonist Therapeutics
PTGX
$5.89B
| $14.7M | 1.36% |
220,600
-219,400
|
|
||
|
24
Soleno Therapeutics
SLNO
$2.1B
| $13.5M | 1.26% |
+200,000
|
|
||
25
Avalo Therapeutics
AVTX
$333M
| $12.8M | 1.19% |
1,006,217
+398,345
|
|